The joumal uses Crossref ited-by service counts times cited of published aricles. Citedby allows Crossref members to find out who is citing their conten. This is the Citing Article List of “Real-world outcomes of lenvatinib plus pembrolizumab in intermediate- and poor-risk metastatic renal cell carcinoma”.
|
No. |
Publication Date |
Citing Article |
|
1 |
2025 |
Future perspectives: targeting fibroblast growth factor receptor 1 to enhance the efficacy of immunotherapy, Exploration of Targeted Anti-tumor Therapy. 1;6:1. https://doi.org/10.37349/etat.2025.1002327 |